-
Patisiran, sold
under the
brand name Onpattro, is a
medication used for the
treatment of
polyneuropathy in
people with
hereditary transthyretin-mediated...
- In late 2016, the company's lead
candidate in
phase III
studies was
patisiran, a
treatment targeting transthyretin (TTR) for the
treatment of TTR-mediated...
-
European Union and in the USA.
Patisiran functions similarly to inotersen. Moderate-certainty
evidence suggests that
patisiran mitigates worsening of peripheral...
-
Strimvelis (2016),
tisagenlecleucel (2017),
voretigene neparvovec (2017),
patisiran (2018),
onasemnogene abeparvovec (2019),
idecabtagene vicleucel (2021)...
-
phospholipase 2G6-****ociated
neurodegeneration (PLAN). The FDA
granted Patisiran (Onpattro)
orphan drug
status and
breakthrough therapy designation due...
-
vutrisiran to
patisiran. 164
ATTRv amyloidosis patients were
randomized 3:1 to
subcutaneous vutrisiran 25 mg
every 3
months or
patisiran 0.3 mg/kg IV infusion...
- disorders.
Patisiran is the
first double stranded siRNA-based
medication approved in 2018 and
developed by
Alnylam Pharmaceuticals.
Patisiran uses the RNAi...
-
first company to have a
siRNA therapy approved by the FDA.
Onpattro (
patisiran) was
approved for the
treatment of
polyneuropathy of
hereditary transthyretin-mediated...
-
developed by
Ionis Pharmaceuticals and
licensed to
Akcea Therapeutics.
Patisiran (sold
under Onpattro) was
developed by
Alnylam Pharmaceuticals, and also...
-
million in Alnylam.
Under the deal,
Genzyme obtained further rights to
patisiran, an RNAi
treatment for transthyretin-mediated
amyloidosis – a condition...
